DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Otros (Other)
Antiviral agents: structural basis of action and rational design
During the last 30 years, significant progress has been made in the development of novel antiviral drugs, mainly crystallizing in the establishment of potent antiretroviral therapies and the approval of drugs inhibiting hepatitis C virus replication. Although major targets of antiviral intervention involve intracellular processes required for the synthesis of viral proteins and nucleic acids, a number of inhibitors blocking virus assembly, budding, maturation, entry or uncoating act on virions or viral capsids. In this review, we focus on the drug discovery process while presenting the currently used methodologies to identify novel antiviral drugs by using a computer-based approach. We provide examples illustrating structure-based antiviral drug development, specifically neuraminidase inhibitors against influenza virus (e.g. oseltamivir and zanamivir) and human immunodeficiency virus type 1 protease inhibitors (i.e. the development of darunavir from early peptidomimetic compounds such as saquinavir). A number of drugs in preclinical development acting against picornaviruses, hepatitis B virus and human immunodeficiency virus and their mechanism of action are presented to show how viral capsids can be exploited as targets of antiviral therapy., Work at CBMSO is supported in part by grants of the Spanish Ministry of Economy and Competitiveness (BIO2010/15542) and the General Directorate for Pharmacy and Medical Products (Ministry of Health, Social Services and Equality) (EC11-025), and an institutional grant from the Fundación Ramón Areces. Continued support to F.G. from the Spanish Comisión Interministerial de Ciencia y Tecnología (SAF2009-13914-C02-02) and Comunidad de Madrid (S-BIO/0214/2006 and S2010-BMD-2457) is gratefully acknowledged., Peer reviewed, Peer Reviewed
Proyecto:
MICINN SAF2009-13914-C02-02